Loading clinical trials...
Loading clinical trials...
A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial
Conditions
Interventions
Rituximab, Temsirolimus, DHAP, intravenous
Locations
9
Germany
University Hospital Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
University of Heidelberg Hospital
Heidelberg, Baden-Wurttemberg, Germany
University Hospital Ulm
Ulm, Baden-Wurttemberg, Germany
University Hospital Erlangen
Erlangen, Bavaria, Germany
Ludwig-Maximilians-University of Munich
Munich, Bavaria, Germany
Technische Universität München
Munich, Bavaria, Germany
Start Date
September 1, 2012
Primary Completion Date
June 1, 2018
Completion Date
July 1, 2018
Last Updated
October 27, 2016
NCT05139017
NCT01804686
NCT05755087
NCT04739813
NCT06785818
NCT06043011
Lead Sponsor
Mathias Witzens-Harig
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions